Le Lézard
Classified in: Health, Science and technology, Business, Covid-19 virus
Subjects: CHI, SVY, TRI, CSR, PSF, SRI, FVT

American Academy of Ophthalmology Leads Global Initiative to Address Worldwide Myopia Epidemic


SAN FRANCISCO, Nov. 11, 2020 /PRNewswire/ -- The number of Americans who are nearsighted has nearly doubled over the last 50 years to about 41.6 percent. This upward trend is evident in nearly every corner of the world, but nowhere near as dramatic as in East and Southeast Asia, where 80 to 90 percent of children and young adults are myopic. If nothing is done to stop this epidemic, it's estimated that almost half of the world will be myopic by 2050. More people in glasses is not the concern, it's the number of people with severe or "high" myopia that's raising the alarm. High myopia raises the risk of vision-threatening eye conditions such as retinal detachment, glaucoma, early cataracts and myopic maculopathy, a leading cause of blindness world-wide. That's why the American Academy of Ophthalmology has brought together experts in myopia from around the world to develop an action plan to delay the onset of myopia in children and slow it down so the most devastating consequences of high myopia can be avoided.

"Myopia needs our focus now," said Richard L. Abbott, MD, leader of the Academy's Myopia Task Force. "Kids who develop myopia early in life and progress to high myopia face an uncertain future. They have a 50 percent greater risk of glaucoma, they are 17 percent more likely to need cataract surgery, and have a 6 times greater risk of retinal detachment and retinal tears."

The time to intervene is in childhood. A study of a school-based program in Taiwan that encouraged kids to spend 11 hours a week outdoors showed that sunlight can decrease myopia progression. Prescribing children low-dose atropine eyedrops or special contact lenses is also effective in slowing disease progression.

"Right now, the world's myopia rates are expected to be closer to Asia's by 2050. It's possible, but it's not inevitable," said Donald Tan, MD, leader of the Academy's Myopia Task Force. "Public health officials need to recognize that high myopia is a disease and promote interventions to reduce its overall incidence and slow progression. Action now can change the future."

Both genetics and environmental factors play key roles in myopia. But the recent, dramatic upswing in cases appears to be driven by environmental factors. People are spending less time outdoors and more time on near-work activities such as screen time and reading. And as the coronavirus sends kids indoors to spend even more time online to attend virtual school, there is growing concern among the eye health community that the pandemic will hasten the myopia epidemic.

While this isn't the first myopia awareness campaign, it is the first effort to coordinate a global health initiative to spread education and foster collaboration to improve treatments.

Led by Drs. Abbott and Tan, the Myopia Task Force includes recognized experts in myopia prevention and treatment, public health experts from around the world, and organization representatives from the American Academy of Family Physicians, the American Academy of Optometry, and the American Academy of Pediatrics. The Task Force has formulated an action plan to address the issue from different perspectives. This includes:

The Academy is pleased to announce that Nevakar Inc., a biopharmaceutical company committed to preserving the vision of children worldwide, is the first company to support this important initiative and has committed $125,000 over the next 5 years to support our educational efforts. "We applaud the Academy's myopia efforts and with this grant want to demonstrate our commitment to this important cause," stated Navneet Puri, PhD, Founder, Chairman and Chief Executive Officer of Nevakar.

Learn more:

About the American Academy of Ophthalmology
The American Academy of Ophthalmology is the world's largest association of eye physicians and surgeons. A global community of 32,000 medical doctors, we protect sight and empower lives by setting the standards for ophthalmic education and advocating for our patients and the public. We innovate to advance our profession and to ensure the delivery of the highest-quality eye care. Our EyeSmart® program provides the public with the most trusted information about eye health. For more information, visit aao.org.

About Nevakar Inc.

Nevakar Inc. is growing as a fully integrated biopharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Founded in 2015, and headquartered in Bridgewater New Jersey, the Company is focused on developing and commercializing innovative products to address unmet medical needs, thereby improving patient care and quality of life. Nevakar utilizes the 505(b)(2) regulatory pathway, along with its proven expertise in the development of novel and proprietary sterile pharmaceutical products to identify, develop, and obtain regulatory approval for its products. Additional information is available at www.nevakar.com.

SOURCE American Academy of Ophthalmology


These press releases may also interest you

at 07:10
The Arena Group announces the return of SURFER with a special print edition due out this summer. First published in 1960, this marks the revival of premium surf journalism, world-class photography, as well as a number of other exciting projects in...

at 07:04
OneConnect Financial Technology Co., Ltd. ("OneConnect" or the "Company") , a leading technology-as-a-service provider for financial institutions in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31,...

at 07:00
The "Payments Market - Global Industry Size, Share, Trends, Opportunity, & Forecast 2019-2029" report has been added to ResearchAndMarkets.com's offering. The Global Payments Market was valued at USD 2.64 Trillion in 2023 and is anticipated to grow...

at 07:00
Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics and diagnostics for infectious diseases, medical countermeasures, and rare disorders, announced today...

at 07:00
Cambridge Bancorp (the "Company"), the parent company of Cambridge Trust Company, today announced unaudited net income of $6.9 million for the three months ended March 31, 2024, a decrease of $1.1 million, or 14.3%, as compared to $8.0 million for...

at 07:00
HEVI Corp. ("HEVI" or the "Company"), a manufacturer of all-electric heavy construction and farming machinery, today announced the Port Authority of New York and New Jersey has agreed to purchase the Company's HEVI GEL-5000 all-electric front loader....



News published on and distributed by: